Dynavax Technologies (NASDAQ:DVAX) jumps 10% premarket on modest volume in reaction to its announcement that dosing is underway in a Phase 1 clinical trial evaluating Medicago’s plant-derived COVID-19 vaccine candidate that includes its CpG 1018 adjuvant (also used in HEPLISAV-B).
As previously reported, the companies plan to explore a broader collaboration aimed at other opportunities.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.